PATENT CLAIM ANALYSIS

Application Number: 15941030
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-10
Patent Classification: ["514", "006700"]

Abstract:
The present invention provides a novel peptide compound having an activating action on GIP receptors and use of the peptide compound as a medicament. Specifically, a peptide containing a sequence represented by the formula (I) or a salt thereof and a medicament comprising the same are provided. P 1 -Tyr-A2-Glu-Gly-Thr-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37-A38-A39-A40-P 2    (I) wherein each symbol is as defined herein.

Claim (Index 8):
The peptide according to  claim 1  represented by formula (I):\n P 1 -Tyr-A2-Glu-Gly-Thr-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37-A38-A39-A40-P 2  \n wherein \n P 1  represents a group represented by formula \n \u2014R A1 , \n \u2014CO\u2014R A1 , \n \u2014CO\u2014OR A1 , \n \u2014CO\u2014COR A1 , \n \u2014SO\u2014R A1 , \n \u2014SO 2 \u2014R A1 , \n \u2014SO 2 \u2014OR A1 , \n \u2014CO\u2014NR A2 R A3 , \n \u2014SO 2 \u2014NR A2 R A3 , or \n \u2014C(\u2550NR A1 )\u2014NR A2 R A3  \n wherein R A1 , R A2 , and R A3  each independently represent a hydrogen atom, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group; \n P 2  represents \u2014NH 2  or \u2014OH; \n A2 represents Aib or D-Ala; \n A6 represents Iva, Phe, or Val; \n A7 represents Ile, Lys, or Val; \n A8 represents Ser; \n A9 represents Asp, Leu, or Phe; \n A10 represents Tyr; \n A11 represents Aib or Ser; \n A12 represents Ile; \n A13 represents Aib, Ala, Gln, Leu, Tyr, or D-Iva; \n 4845-9345-2384.1 A14 represents Leu; \n A15 represents Asp, Glu, Lys, Ser, or Tyr; \n A16 represents Arg or Lys; \n A17 represents Aib, Gln, or Ile; \n A18 represents Ala or His; \n A19 represents Gln or Ser; \n A20 represents Aib, Ala, or Gln; \n A21 represents Asn, Asp, Glu, Leu, or Ser; \n A22 represents Phe or aMePhe; \n A23 represents Ile or Val; \n A24 represents Arg, Asn, Lys, or Lys(Ac); \n A25 represents Trp; \n A26 represents Aib, Iva, or Leu; \n A27 represents Leu; \n A28 represents Ala, Arg, Lys, or Lys(Ac); \n A29 represents Gln or Gly; \n A30 represents Arg, Gly or a deletion; \n A31 represents Pro or a deletion; \n A32 represents Ser or a deletion; \n A33 represents Ser or a deletion; \n A34 represents Gly or a deletion; \n A35 represents Ala or a deletion; \n A36 represents Pro or a deletion; \n A37 represents Pro or a deletion; \n A38 represents Pro or a deletion; \n A39 represents Lys, Ser or a deletion; \n A40 represents Arg, Lys, or a deletion, and \n any one or two amino acids selected from A12, A14 and A17 optionally represent Lys(R), and R represents a substituent group, \n or a salt thereof.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 90.0
- Lexical Diversity: 1.36735
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['16303975', '14780579', '14125061', '14800627', '14287514']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8545437220911258
- 35 USC 102 Novelty (BERT): 0.6232606061310638
- Combined Prediction Score: 0.8314154104951197
- Mean Citation Score: 634.65795
- Max Citation Score: 721.8596
- Similarity Product: 484.2936172106743

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test